<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978337</url>
  </required_header>
  <id_info>
    <org_study_id>CR109031</org_study_id>
    <secondary_id>53718678RSV2008</secondary_id>
    <secondary_id>2020-005980-30</secondary_id>
    <nct_id>NCT04978337</nct_id>
  </id_info>
  <brief_title>A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection</brief_title>
  <acronym>PRIMROSE</acronym>
  <official_title>A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Who Are at High Risk for RSV-related Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with&#xD;
      respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory&#xD;
      tract disease (LRTD) symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rilematovir is an investigational RSV specific fusion inhibitor currently in development for&#xD;
      the treatment of RSV infection in both adult and pediatric populations. The study will&#xD;
      include a Screening period (Day -1 to Day 1), a Treatment period (Day 1 to Day 7/8 [depending&#xD;
      on timing of first dose]), and a Follow-up period (Day 8/9 to Day 35). The total study&#xD;
      duration of the study for each participant will be up to 35 days. The study will evaluate&#xD;
      efficacy and safety of RSV in adult outpatients (18-85 years) who are at high risk of RSV&#xD;
      related disease progression and have at least moderate RSV disease. The efficacy assessments&#xD;
      include evaluation with electronic patient-reported outcome (ePRO) and the safety assessments&#xD;
      include evaluations of physical examinations, vital signs, electrocardiograms, clinical&#xD;
      laboratory tests, and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease (LRTD) Symptoms as Assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ Symptom Scale)</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of RSV LRTD symptoms (that is, cough, short of breath, wheezing, coughing up phlegm [sputum]) as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Post-Baseline RSV-related Complications</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with post-baseline RSV-related pulmonary and extrapulmonary complications will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with New Antibiotic Use, or New or Increased Use in Bronchodilator/Nebulizer, Systemic Corticosteroids, or Home Oxygen Supplementation</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with new antibiotic use, or new or increased use in bronchodilator/nebulizer, systemic corticosteroids, or home oxygen supplementation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Unscheduled Outpatient Clinic Visits, Emergency Room Visits or Hospitalization for Respiratory Infection</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with unscheduled outpatient clinic visits, emergency room visits or hospitalization for respiratory infection will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting a Composite Endpoint of Either Developing RSV-Related Complications and/or Needing RSV-related Medical Attendance</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants meeting a composite endpoint of either developing RSV-related complications (pulmonary &amp; extra pulmonary) and/or needing RSV-related medical attendance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) as Measure of Safety and Tolerability</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Clinical Laboratory Tests</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with abnormalities in clinical laboratory parameters (including hematology, chemistry and urinalysis) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Electrocardiograms (ECGs)</measure>
    <time_frame>From initiation of study treatment up to Day 14</time_frame>
    <description>Percentage of participants with abnormalities in ECGs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Physical Examination</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with abnormalities in physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Vital Signs</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with abnormalities in vital signs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in Severity of the RSV LRTD Symptoms as Assessed by the Participant Using the RiiQ Symptom Scale Score</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>Change from baseline over time in severity of the RSV LRTD symptoms as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of LRTD Symptoms and 2 Systemic symptoms as Assessed by RiiQ Symptom Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of LRTD symptoms and 2 systemic symptoms (feeling feverish and fatigue) as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of the Overall RSV Symptoms (Upper Respiratory Tract Disease [URTD], LRTD, and 2 Systemic Symptoms) as Assessed by RiiQ Symptom Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of the overall RSV symptoms (URTD [sore throat and nasal congestion], LRTD, and 2 systemic symptoms [feeling feverish and fatigue]) as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of all RSV Symptoms as Assessed by RiiQ Symptom Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of all RSV symptoms as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale and it can be scored as a mean of all scores (total symptom scale score) or 2 subscales scores that is respiratory symptoms and systemic symptoms. Respiratory symptoms subscale score is the mean of 6 symptoms, that is, 2 URTD symptoms (nasal congestion and sore throat) and 4 LRTD symptoms (cough, wheezing, shortness of breath, and coughing up phlegm/sputum) whereas systemic symptom subscale score is the mean of 7 systemic symptoms (headache, feeling feverish, neck pain, body aches and pain, fatigue/tiredness, interrupted sleep, and loss of appetite). Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of each Separate RSV LRTD Symptom as Assessed by RiiQ Symptom Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of each separate RSV LRTD symptom as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Respiratory Infection Symptoms as Assessed by Patient Global Impression of RSV Severity (PGI-S) Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to resolution of respiratory infection symptoms as assessed by PGI-S scale score will be reported. PGI-S is a single item patient-reported outcome (PRO) aimed to capture how severe the participant's respiratory infection symptoms at their worst scored that day. PGI-S is a 5-point ordinal response scale ranging from no symptoms today (0), mild (1), moderate (2), severe (3), and very severe (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Pre-existing Health (Status) for all RSV Symptoms as Assessed by RiiQ Symptom Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to return to pre-existing health (status) for all RSV symptoms as assessed by RiiQ symptom scale score will be reported. RiiQ is a 4-point scale. Each symptom is rated on the scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in RSV Disease as Assessed by Patient Global Impression of Change (PGI-C) Scale Score</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to improvement in RSV disease as assessed by PGI-C scale will be reported. PGI-C is a single item patient-reported outcome (PRO) aimed to capture the participant's perceptions of improvement or deterioration in the severity of RSV symptoms compared to before the participant started taking the study intervention. PGI-C is a 7-point ordinal response scale ranging from much better (3), somewhat better (2), a little better (1), about the same (0), a little worse (-1), somewhat worse (-2), and much worse (-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time for the Health-Related Quality of Life (HRQOL) as Assessed by 5 Level EuroQol 5 Dimension (EQ-5D-5L)</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>EQ-5D-5L includes 6 questions that provide a profile on 5 HRQOL domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems. It also contains a visual analog scale (VAS) of 'how good or bad is your health today' on a scale ranging from 0 (the best health you can imagine) to 100 (the worst health you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time for the RiiQ Impact Scales</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>RiiQ impact scale consists of 3 scales (that is, RiiQ impact on daily activities ranging from 0 [no difficulty] to 3 [great difficulty]; RiiQ impact on emotional scale ranging from 0 [not at all] to 3 [extremely], and RiiQ impact on others scale ranging from 0 [not at all concerned] to 3 [extremely concerned]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Usual Health as Assessed by the 'Adult RSV Return to Usual Health' Question</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to return to usual health as assessed by the 'adult RSV return to usual health' question (that is Have you returned to your usual health today? with an option of &quot;Yes&quot; or &quot;No&quot;) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Usual Activities as Assessed by the 'Adult RSV Return to Usual Activities' Question</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to return to usual activities as assessed by the 'adult RSV return to usual activities' question (that is Have you returned to your usual activities today? with an option of &quot;Yes&quot; or &quot;No&quot;) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to No or Mild Impact of RSV-related Disease on Daily Activities, Emotions, and Social Relationships as Assessed by RiiQ Impact Scales</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Time to no or mild impact of RSV-related disease on daily activities, emotions, and social relationships as assessed by RiiQ impact scales will be reported. RiiQ impact scale is to understand the impact of an acute episode of RSV infection using the 3 scales (that is, RiiQ impact on daily activities ranging from 0 [no difficulty] to 3 [great difficulty]; RiiQ impact on emotional scale ranging from 0 [not at all] to 3 [extremely], and RiiQ impact on others scale ranging from 0 [not at all concerned] to 3 [extremely concerned]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Viral Load Area Under the Curve (AUC) from Immediately Prior to First Dose of Study Intervention (Baseline) Through Days 3, 5 and 8</measure>
    <time_frame>Baseline, Days 3, 5 and 8</time_frame>
    <description>RSV viral load AUC from immediately prior to first dose of study intervention (baseline) through Days 3, 5 and 8 will be reported. RSV viral load will be assessed by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) assay of nasal mid turbinate swab samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline over Time in RSV Viral Load</measure>
    <time_frame>Baseline up to Day 21</time_frame>
    <description>Change from baseline over time in RSV viral load will be assessed by qRT-PCR assay in the mid-turbinate nasal swabs samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable RSV Viral Load</measure>
    <time_frame>From initiation of study treatment up to Day 21</time_frame>
    <description>Percentage of participants with undetectable RSV viral load at each time point that a swab is planned to be collected will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Post-baseline Sequence Changes in the RSV F Gene</measure>
    <time_frame>From initiation of study treatment up to Day 21</time_frame>
    <description>Percentage of participants with post-baseline sequence changes in the RSV F gene will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Plasma Concentration (Ctrough) of Rilematovir</measure>
    <time_frame>Days 1, 3 and 8</time_frame>
    <description>Ctrough is defined as the predose plasma concentration of rilematovir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Rilematovir</measure>
    <time_frame>Days 1, 3 and 8</time_frame>
    <description>Cmax is defined as the maximum plasma concentration of rilematovir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of Administration of Rilematovir up to 12 hours Post Dosing (AUC[0-12h])</measure>
    <time_frame>Days 1, 3 and 8</time_frame>
    <description>AUC(0-12h) is defined as area under the curve of administration of rilematovir up to 12 hours post dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Number and Type of Medical Encounters</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with number and type of medical encounters (example, increased nursing visits at home, emergency room visit) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Shift in any Care Setting</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with shift in any care setting (example, from no assistance to use of skilled home nurse or assisted home living) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Hospitalization for Respiratory or Other Reasons</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants requiring hospitalization for respiratory or other reasons will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Duration of hospitalization (total days length of stay, including incidence and where feasible duration by wards, example, intensive care unit [ICU]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Use of Antibiotics</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with treatment-emergent use of antibiotics will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment-emergent Use of Antibiotics</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Duration of treatment-emergent use of antibiotics will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent New Use or Increased Dose of Systemic or Inhaled Corticosteroids and Bronchodilators</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with treatment-emergent new use or increased dose of systemic or inhaled corticosteroids and bronchodilators will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment-emergent New Use or Increased Dose of Systemic or Inhaled Corticosteroids and Bronchodilators</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Duration of treatment-emergent new use or increased dose of systemic or inhaled corticosteroids and bronchodilators will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with New or Increased Use of Oxygen Therapy</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Percentage of participants with new or increased use of oxygen therapy will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Oxygen Supplementation</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Duration of oxygen supplementation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Selected Post-baseline Emergent (After Start of Study Intervention) Medical Resource Utilization</measure>
    <time_frame>From initiation of study treatment up to Day 35</time_frame>
    <description>Duration of selected post-baseline emergent (after start of study intervention) MRU (example, increased nursing visits at home, emergency room visit) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Treatment A: Rilematovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilematovir</intervention_name>
    <description>Rilematovir 250 mg will be administered orally.</description>
    <arm_group_label>Treatment A: Rilematovir</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to rilematovir will be administered orally.</description>
    <arm_group_label>Treatment B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presented to the healthcare facility with symptoms suggestive of a diagnosis of acute&#xD;
             respiratory syncytial virus (RSV) infection&#xD;
&#xD;
          -  Has at least 2 symptoms of lower respiratory tract disease (LRTD), one of which must&#xD;
             be scored as at least 'moderate' if the symptoms did not pre-exist before RSV onset,&#xD;
             or one of which is scored worse than usual if the symptoms pre-existed&#xD;
&#xD;
          -  Tested positive for RSV infection using a molecular-based diagnostic assay (polymerase&#xD;
             chain reaction [PCR] or other) on a bilateral nasal mid-turbinate swab sample&#xD;
&#xD;
          -  Has at least one of the following high-risk conditions that predispose them to&#xD;
             RSV-related disease progression: a. age greater than or equal to (&gt;=) 65 years, b.&#xD;
             congestive heart failure (CHF), c. chronic obstructive pulmonary disease (COPD), d.&#xD;
             asthma&#xD;
&#xD;
          -  Randomized to study intervention treatment within 72 hours after onset of any of the&#xD;
             RSV symptoms or worsening of pre-existing symptoms&#xD;
&#xD;
          -  Not be hospitalized during screening (emergency room or hospital observation status&#xD;
             for an anticipated duration of less than [&lt;] 24 hours are not considered as&#xD;
             hospitalization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to rilematovir or to any of the&#xD;
             excipients of rilematovir or placebo formulation&#xD;
&#xD;
          -  Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial&#xD;
             arrhythmia, or sustained ventricular arrhythmia&#xD;
&#xD;
          -  Participant has known or suspected (from medical history or participant examination)&#xD;
             chronic or acute hepatitis B or C infection&#xD;
&#xD;
          -  Immunocompromised conditions&#xD;
&#xD;
          -  Living in institutional care or assisted living facility and also receiving acute care&#xD;
             management for any respiratory condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahaba Research Inc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiel Family and Sports Medicine Clinical Research Advantage</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMD Clinical Trials</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope clinical Research LLC</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Clinical Research, LLC</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moonshine Research Center, Inc</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Quality Research Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research, Inc</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Partners Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Center Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute Of South Florida, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Cinical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center Inc</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andres Patron D.O. P.A.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center Inc</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santos Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privia Medical Group, LLC</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privia Medical Group, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>Georgia</state>
        <zip>30214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pramukh Clinical Research, LLC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southcoast Health</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privia Medical Group, LLC</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Clinical Research, Inc.</name>
      <address>
        <city>White Marsh</city>
        <state>Maryland</state>
        <zip>21162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Fields Family Medicine</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Urgent Care Clemmons</name>
      <address>
        <city>Clemmons</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health Network</name>
      <address>
        <city>Mocksville</city>
        <state>North Carolina</state>
        <zip>27028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Primary Care</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonologist, Critical Care, and Sleep Medicine</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Clinical Research</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Care, PLLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Level Urgent Care</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Research LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Pulmonary Group</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Clinical Research LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rio Grande Valley Clinical Research Institute</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <zip>78577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javara</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javara</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCT Research at Olympus Family Medicine</name>
      <address>
        <city>Holladay</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCT Research at South Ogden Family Medicine</name>
      <address>
        <city>South Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javara</name>
      <address>
        <city>Forest</city>
        <state>Virginia</state>
        <zip>24551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Institute For Research &amp; Innovation - Rockwood Clinic - Cheney</name>
      <address>
        <city>Cheney</city>
        <state>Washington</state>
        <zip>99004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institue for Research &amp;amp; Innovation</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE - Centro de Alergia y Enfermedades Respiratorias</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>1414</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación CENIT para la Investigación en Neurociencias</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>1125</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INAER - Investigación en Alergias y Enfermedades Respiratorias</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto DAMIC</name>
      <address>
        <city>Córdoba Capital</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IERIM - Instituto de Enfermedades Respiratorias e Investigación Médica</name>
      <address>
        <city>Florencio Varela</city>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto FIDES</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ave Pulmo</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7602DCK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Respiratorio Quilmes</name>
      <address>
        <city>Quilmes</city>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Respire</name>
      <address>
        <city>San Fernando</city>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mayo de UMCB</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IHE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Modelo de Cardiologia</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones en Patologias Respiratorias</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESIM - Centro de Salud e Investigaciones Médicas</name>
      <address>
        <city>Santa Rosa</city>
        <zip>L6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMER - Centro Médico de Enfermedades Respiratorias</name>
      <address>
        <city>Vicente López</city>
        <zip>1602</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Felício Rocho</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L2IP - Instituto de Pesquisas Clínicas</name>
      <address>
        <city>Brasília</city>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Universidade de Caxias do Sul</name>
      <address>
        <city>Caxias do Sul</city>
        <zip>95070 560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São José</name>
      <address>
        <city>Criciúma</city>
        <zip>88801-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servico de Infectologia e Controle de Infeccao Hospitalar de Curitiba-Centro Medico Sao Francisco</name>
      <address>
        <city>Curitiba</city>
        <zip>80810-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas em Moléstias Infecciosas</name>
      <address>
        <city>Natal</city>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Psiquiatria e Pesquisas Sandra Ruschel</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22270-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pesquisare Saude</name>
      <address>
        <city>Santo André</city>
        <zip>09080-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo Ltd. Haskovo</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Sv. Ivan Rilski' Kozloduy EOOD</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Stamen Iliev AD</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pulmonary Diseases - Pernik</name>
      <address>
        <city>Pernik</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT of Pneumo-phthisiatric Diseases Dr Dimitar Gramatikov - Ruse, EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pulmonary Diseases - Troyan EOOD</name>
      <address>
        <city>Troyan</city>
        <zip>5600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC 'Sv. Ivan Rilski', OOD</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K Gupta Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG Am Standort IFS - Interdisziplinäres Facharztzentrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut</name>
      <address>
        <city>Leipzig</city>
        <zip>04249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Weimer</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSlim GmbH</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szigony utcai Felnott Haziorvosi Rendelo Csaladgyogyasz Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Észak-Közép-budai Centrum, Új Szent János Kórház és Szakrendelő-Tüdőgondozó Intézet és Szűrőállomás</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strázsahegy Medicina Bt</name>
      <address>
        <city>Budapest</city>
        <zip>1171</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omnimodus Elixír Kft.</name>
      <address>
        <city>Csorna</city>
        <zip>9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Chennai</city>
        <zip>600095</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hindusthan Hospital</name>
      <address>
        <city>Coimbatore</city>
        <zip>641028</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinaya Hospital and Research Center</name>
      <address>
        <city>Mangalore</city>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lata Mangeshkar Hospital</name>
      <address>
        <city>Nagpur</city>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifepoint Multispecialty Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411057</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAPS Pramukhswami Hospital</name>
      <address>
        <city>Surat</city>
        <zip>395009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Polo Universitario San Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Di Modena, Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishifukuoka Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagata Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terada Clinic Respiratory Medicine &amp; General Practice</name>
      <address>
        <city>Himeji-shi</city>
        <zip>670-0849</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kasumigaura Medical Center</name>
      <address>
        <city>Ibaraki</city>
        <zip>300-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamoike ENT allergy clinic</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkomonji hospital</name>
      <address>
        <city>Kitakyusyu</city>
        <zip>800-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koyama Medical Clinic</name>
      <address>
        <city>Nagano</city>
        <zip>390-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama City General Medical Center Okayama City Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Shinagawa Hospital</name>
      <address>
        <city>Shinagawa-ku</city>
        <zip>140-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KKR Takamatsu Hospital</name>
      <address>
        <city>Takamatsu-shi</city>
        <zip>760-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azuma Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenshinkai Minamino Cardiovascular Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>192-0038</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Dr. Juan I. Menchaca</name>
      <address>
        <city>Gualajadara</city>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RM Pharma Specialists</name>
      <address>
        <city>Mexico</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Centro Regiomontano de Investigación S.C</name>
      <address>
        <city>Monterrey</city>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Pediatryczno-Alergologiczny</name>
      <address>
        <city>Bialystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Poradnie Specjalistyczne ATOPIA</name>
      <address>
        <city>Krakow</city>
        <zip>31159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ w Lecznej</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Innowacyjnych Terapii Sp. z o.o.</name>
      <address>
        <city>Piaseczno</city>
        <zip>05500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych, Osrodek Badan Wczesnej Fazy</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #25 of the Nevsky District of SPB</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eco-safety Ltd</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Healthcare Institution 'City Polyclinic #106'</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198328</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC 'Terafarm'</name>
      <address>
        <city>Stavropol</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of the Yaroslavl Region &quot;Clinical Hospital #9&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150042</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queenswood Clinical Trial Centre</name>
      <address>
        <city>Gauteng</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MERC Kempton Park</name>
      <address>
        <city>Gauteng</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahmed Alkadi Hospital</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4058</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice - Dr. Peter Sebastian</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mzansi Ethical Research Centre</name>
      <address>
        <city>Middelburg</city>
        <zip>1055</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Clin Trials Pretoria</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. de Elche</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Univ. de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Univ. de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSite Helsingborg</name>
      <address>
        <city>Helsingborg</city>
        <zip>25220</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSite</name>
      <address>
        <city>Malmo</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSmart Sweden AB</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Tropical Diseases</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Disease Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Pathumwan</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Medical Faculty</name>
      <address>
        <city>Kocaeli</city>
        <zip>41001</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem Mehmet Ali Aydinlar University</name>
      <address>
        <city>Kucukcekmece</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk National Medical University, Ivano-Frankivsk City Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of LL Company 'Scientific Medical Center-Your Doctor'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Unit Of Company 'Kharkiv Tractor Plant', Kharkiv Medical Academy Of Postgraduate Education</name>
      <address>
        <city>Kharkiv</city>
        <zip>61106</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mi 'Kherson City Clinical Hospital Of E.E. Karabelesh'</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center LLC 'Harmony of Beauty'</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Consylium Medical'</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinic of State Joint Stock Holding Company 'Artem'</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Policlinic #20</name>
      <address>
        <city>Odesa</city>
        <zip>65114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Clinical Hospital HSEI of Ukraine Ukrainian Medical Stomatological Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1-A City Clinical Hospital - Ukrainian Medical Stomatology Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNPE Central City Hospital of Rivne City Council, Medical and Diagnostic Hepatological Center</name>
      <address>
        <city>Rivne</city>
        <zip>33018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil City Municipal Emergency Hospital Infectious Dept. with Ward of Intensive Care</name>
      <address>
        <city>Ternopil</city>
        <zip>46008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VNMUn.af.Pyrogova,CNE Vinnytsia Regional Clinical Hospital n.af.Pyrogova Vinnytsia Regional Council</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KU 6 miska klinichna likarnia ZMR</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Central City Hospital #1</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

